VMD Stock Analysis: Buy, Sell, or Hold?
VMD - Viemed Healthcare, Inc. Common Shares
$9.37
0.12 (1.30%)
▲
5d:
+2.07%
30d:
+7.7%
90d:
+28.36%
BUY
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 06, 2026
Get Alerted When VMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VMD shows positive signals but monitor for confirmation. Market pricing in 3.6% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: VMD shows positive signals but monitor for confirmation. Market pricing in 3.6% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$16.18
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$10.05
6.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: VMD is currently trading at $9.37, which is considered slightly high relative to its 30-day fair value range of $8.57 to $9.41. From a valuation perspective, the stock is trading at a premium (Forward PE: 14.9) compared to its historical average (13.4). At these levels, the market is pricing in 3.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, VMD is in a strong uptrend. Immediate support is located at $8.62, while resistance sits at $9.92.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (12th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.00 (+40.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VMD is in a strong uptrend. Immediate support is located at $8.62, while resistance sits at $9.92.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (12th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.00 (+40.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$8.57 -
$9.41
Company Quality Score
56/100
(HOLD)
Options IV Signal
12th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
72.7%
All Signals
- BULLISH: Options cheap (IV 12th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 40.5% below Wall St target ($13.00)
- NEUTRAL: Market pricing in 3.6% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$8.57 -
$9.41
Current vs Fair Value
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.56
(6.0%)
Support & Resistance Levels
Support Level
$8.62
Resistance Level
$9.92
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.92
Wall Street Target
$13.00
(+40.5%)
Revenue Growth (YoY)
25.5%
Earnings Growth (YoY)
29.8%
Profit Margin
5.5%
Valuation Premium vs History
+3.6% premium
PE vs Historical
14.9 vs 13.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.6%
(market-implied from PE analysis)
1-Year Target
$9.58
(+4%)
2-Year Target
$9.93
(+7%)
3-Year Target
$10.29
(+11%)
3-Yr Target (if PE normalizes)
(PE: 15→13)
PE COMPRESSION
$9.24
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 29.2%)
$29.93
(+224%)
Base:
(SPY PE: 14.9, Growth: 29.2%)
$19.93
(+116%)
Bear:
(PE: 12.7, Growth: 29.2%)
$16.94
(+83%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (24x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 23.54 | Current EPS (TTM): $0.37
Bull Case
$16.05
(+75%)
Analyst growth 67.6%, PE expands to 25.9
Base Case
$14.60
(+59%)
Market implied 67.6%, PE stable at 23.5
Bear Case
$5.92
(-36%)
Severe decline -20.0%, PE contracts to 20.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: March 30, 2026 2:52 PM ET
Data refreshes hourly during market hours. Next update: 3:52 PM
Data refreshes hourly during market hours. Next update: 3:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 60 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 56 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 51 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 63 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$354 | 48 HOLD |
